Dicer1 Nanocarrier System Enhances Wound Closure and Cell Viability
Summary: A new study in ACS Omega (Sept 2025) explores how Dicer1 overexpression, delivered via a novel peptide-based nanocarrier (M9-DICER1-CS-A), improves wound closure and cellular activity in vitro. Researchers show that re-engineered HaCaT keratinocytes embedded within a hydrogel scaffold demonstrate persistent viability, proliferation, and upregulation of wound-healing genes—supporting future applications in treating impaired or diabetic wounds.
Key Highlights:
- Dicer1 as a regulator: Low Dicer1 expression correlates with stalled wounds in diabetes; experimental overexpression promoted faster wound closure and gene upregulation.
- Nanocarrier vs. Lipofectamine: The custom peptide carrier (M9-DICER1-CS-A) proved less toxic than Lipofectamine 2000 while maintaining efficient nucleic acid delivery and condensation.
- Nanocomplex characteristics: Approximately 200 nm in size, PDI ~0.25, with positive surface charge (~18–20 mV), stable yet responsive to release triggers (heparin challenge).
- Hydrogel integration: Engineered HaCaT cells grown in a polysaccharide hydrogel matrix maintained viability and showed time-dependent proliferation, creating a cell-laden wound-healing construct.
- Clinical potential: This strategy points toward safe, non-viral, peptide-based delivery systems combined with biomaterial scaffolds as a translational avenue for chronic or diabetic wound management.
Read the full article in ACS Omega
Keywords:
Dicer1,
peptide nanocarrier,
hydrogel scaffold,
keratinocytes,
diabetic wounds,
gene therapy,
ACS Omega